University at Buffalo - The State University of New York
Skip to Content

Prasad to be recognized with first UB Innovation Impact Award

Groundbreaking research in nanoparticles offers platform for new cancer treatment model

By Michael Andrei

Release Date: February 26, 2015

“Professor Prasad’s discoveries in nanomedicine have great potential and could lead to breakthroughs in terms of detecting, diagnosing and treating various forms of cancer.”
Venu Govindaraju, interim vice president for research and economic development
University at Buffalo
Download High-Res Image:

Paras Prasad, PhD, executive director of the Institute for Lasers, Photonics and Biophotonics at UB. Credit: Douglas Levere

BUFFALO, N.Y. – The University at Buffalo will present its inaugural Innovation Impact Award to Paras Prasad, PhD, executive director of the Institute for Lasers, Photonics and Biophotonics at UB.

The award ceremony will be from 3:30–5:30 p.m., March 6, in the Center for the Arts Screening Room on the UB North Campus.  

Prasad, a SUNY Distinguished Professor and one of the world’s pre-eminent scientists in nanomedicine, will be recognized for his work in developing the use of magnetic and laser-activated nanoparticles for cancer diagnosis and treatment.

This technology was licensed to UB spinoff Nanobiotix, a French publicly traded company and leader in nanomedicine that has maintained close contact with Prasad while working to develop these and other new nanomedicine products.

“Professor Prasad’s discoveries in nanomedicine have great potential and could lead to breakthroughs in terms of detecting, diagnosing and treating various forms of cancer,” said Venu Govindaraju, UB interim vice president for research and economic development. “His work also demonstrates how university researchers can drive innovation and economic development within our region and around the world.”

A professor of chemistry, physics, medicine and electrical engineering, Prasad developed the magnetic and laser-activated nanoparticles in the 1990s with partners including Nanobiotix founder Laurent Levy, PhD, who served as a postdoctoral researcher in Prasad’s lab.

As part of the agreement to license nanomedicine technology to Nanobiotix, UB received company stock. The university sold the shares for $1.35 million in 2014, with the majority returning to UB to be reinvested in research, in accordance with university policy.

Innovation Impact Award

The UB Innovation Impact Award is given in special recognition of high-impact innovations created by university faculty and members of the university research community. UB encourages and facilitates the transfer of discoveries into enterprises that create value and provide products or services that benefit the public good and contribute to the development of products that will benefit people around the world. 

 

Media Contact Information

Michael Andrei
News Content Manager
Tel: 716-645-9068
mandrei@buffalo.edu

Media Relations (University Communications)
330 Crofts Hall (North Campus)
Buffalo, NY 14260-7015
Tel: 716-645-6969
Fax: 716-645-3765
ub-news@buffalo.edu